Table 1:
Patient and tumour characteristics of patients with clinical Stage IIIA NSCLC, treated with CRT or TT
| Characteristics | CRT | TT | All | P-value |
|---|---|---|---|---|
| (N = 196) | (N = 61) | (N = 257) | ||
| Age, years (median, IQR) | 65 (58–72) | 61 (55–67) | 64 (57–71) | 0.004 |
| Gender (no. of patients, %) | 1 | |||
| Male | 115 (59) | 36 (59) | 151 (59) | |
| Female | 81 (41) | 25 (41) | 106 (41) | |
| WHO performance (no. of patients, %) | 0.08 | |||
| 0 | 68 (35) | 14 (23) | 82 (32) | |
| 1 | 127 (65) | 12 (20) | 139 (54) | |
| Unknown | 1 (1) | 35 (57) | 36 (14) | |
| Charlson comorbidity index (no. of patients, %) | 0.02 | |||
| 2 | 7 (4) | 7 (11) | 14 (5) | |
| 3 | 13 (7) | 5 (8) | 18 (7) | |
| 4 | 3 (2) | 3 (5) | 6 (2) | |
| 5 | 1 (1) | 1 (2) | 2 (1) | |
| 6 | 70 (36) | 21 (34) | 91 (35) | |
| 7 | 62 (32) | 15 (25) | 77 (30) | |
| 8 | 19 (10) | 6 (10) | 25 (10) | |
| 9 | 17 (9) | 2 (3) | 19 (7) | |
| 10 | 4 (2) | 1 (2) | 5 (2) | |
| Preoperative FEV1 (% of predicted: median, IQR) | 76 (62–94) | 90 (76–102) | 80 (65–96) | 0.002 |
| GTV (cc, median, IQR) | 95 (53–172) | 74 (38–130) | 93 (49–165) | 0.07 |
| cT-stage (no. of patients, %) | 0.003 | |||
| T0/x | 4 (2) | 1 (2) | 5 (2) | |
| T1 | 39 (20) | 6 (10) | 45 (18) | |
| T2 | 79 (40) | 17 (28) | 96 (37) | |
| T3 | 39 (20) | 18 (30) | 57 (22) | |
| T4 | 35 (18) | 19 (31) | 54 (21) | |
| cN-stage (no. of patients, %) | 0.01 | |||
| N0 | 26 (13) | 16 (26) | 42 (16) | |
| N1 | 19 (10) | 10 (16) | 29 (11) | |
| N2 | 151 (77) | 35 (57) | 186 (72) | |
| Pathologically proven N2 stage (no. of patients, %) | 0.29 | |||
| Yes | 111 (56.6) | 29 (47.5) | 140 (54.5) | |
| No | 83 (42.3) | 32 (52.5) | 115 (44.7) | |
| Unknown | 2 (1.2) | 0 (0) | 2 (0.7) | |
| Pre-treatment histology (no. of patients, %) | 0.01 | |||
| AC | 54 (28) | 22 (36) | 76 (30) | |
| SCC | 78 (40) | 12 (20) | 90 (35) | |
| NSCLC NOS | 64 (33) | 27 (44) | 91 (35) | |
| Radiological response after CRT (no. of patients, %) | 0.06 | |||
| Complete response | 19 (10) | 11 (18) | 30 (12) | |
| Partial response | 108 (55) | 10 (16) | 118 (46) | |
| Stable disease or progression | 18 (9) | 5 (8) | 23 (9) | |
| Unknown | 51 (26) | 35 (57) | 86 (33) |
AC: adenocarcinoma; cN-stage: clinical nodal stage; cT-stage: clinical tumour stage; CRT: chemoradiotherapy; FEV1: forced expiratory volume in 1 second; GTV: gross tumour volume; IQR: interquartile; NSCLC NOS: non-small cell lung cancer not otherwise specified; SCC: squamous cell carcinoma; TT: trimodality treatment.